NIDA-AACAP Resident Training Award Application

NIDA-AACAP Resident Training Award in Substance Use Disorders, supported by the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH) and sponsored by AACAP

The NIDA-AACAP Resident Training Award in Substance Use Disorder, supported by the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH) and sponsored by AACAP, seeks to support the development of expertise in substance use disorders (SUD) through completion of a mentored experience and project.

The goals of this award are:
1. To promote and improve knowledge of evidence-based SUD treatment among health care providers;
2. To promote dissemination of substance use disorder research findings;
3. To promote the adoption of evidence-based approaches in medical settings; and
4. To facilitate the professional growth and development of future clinician leaders in SUD management and research.

For early investigators, obtaining funding for training and mentored experiences is critical, but it is also the most difficult to secure. The NIDA-AACAP Training Award provides up to one year of support to general and child and adolescent psychiatry residents to support training in dissemination of research. Through support from this program, the awardee(s) will:
- Engage in a Mentored opportunity to learn about key areas of SUD and SUD treatment strategies through systematic literature review, attendance at conferences and workshops, and interaction with leading experts in the field.

This award cannot be used to conduct basic or clinical research studies or trials. Awardees are to develop and execute a plan designed to increase their knowledge of SUD and SUD treatment and complete a project aimed at improving the dissemination and/or adoption of SUD research findings. Secondary data analysis may be completed in pursuit of these aims, provided the project proposed is eligible for IRB exemption and has a dissemination/adoption focus. The award offers up to $10,000 for program support (award amount includes travel to AACAP’s 68th Annual Meeting in Atlanta, GA, October 25-30, 2021; and travel to the NIDA Clinical Trials Network's Annual Meeting in Bethesda, MD, April 26-28, 2021) and $2,000 for a mentor stipend. (All awards are contingent upon the receipt of adequate funding support.)

PURPOSE OF THE AWARD

The purpose of this award is to:
- Provide the trainee with a mentored opportunity to learn about key areas of SUD and SUD treatment strategies through systematic literature review, attendance at conferences and workshops, and interaction with leading experts in the field.
- Provide the trainee with experience that eventually fosters interest in either a clinical career providing evidence-based management of SUD in medical settings or potentially stimulates interest in securing a NIH career development or other grant award to pursue implementation and related research in the field of substance misuse and substance use disorder in subsequent years.
• Provide the trainee with a mentored experience in effective dissemination of existing or emerging research finding and/or the implementation/adoptions of research in clinical practice. Applicants are encouraged to develop projects that address or improve upon current gaps in the dissemination of research findings or implementation/adoptions of evidence-based treatment practices. The projects will be presented via poster at the AACAP Annual Meeting.

INSTRUCTIONS FOR APPLICATION SUBMISSION

Please submit the following required items to Sarah Hellwege, AACAP’s Deputy Director, Research, Training, and Education, at research@aacap.org by 11:59 pm EST on Wednesday, November 4, 2020.

Note: All letters submitted electronically must contain valid signatures.

Instructions for Application Submission

Candidates cannot have had previous or simultaneous funding from the National Institutes of Health (NIH) or research funding sources. Eligible candidates may not have a training award. Applications that do not adhere to the following guidelines will not be reviewed.

• Completed award application.
• Candidate section, including a personal statement and interest in the substance use field, of no more than two pages (single spaced, no less than 12 pt. font and 1” margins).
• A proposal of no more than five pages (single spaced, no less than 12 pt. font and 1” margins) including:
  o Project title and description that includes the following sections: objectives, background, project rationale, project method, and an implementation and dissemination plan.
  o A detailed project timeline with tentative dates of all activities for the proposed project.
  o A budget and budget justification containing sufficient detail so that each item can be judged separately. Computer related items (e.g., personal computers, printers, modems, etc.) are unlikely to receive budget approval. Salary support will not be provided for the mentor. No indirect costs for the institution will be provided. Typical budget items may include, but are not limited to, honoraria, travel expenses, etc.
  o Literature cited page in proposal
• A listing of any current and/or previous award funding.
• The applicant’s current curriculum vitae or biosketch
• The mentor’s current curriculum vitae or biosketch
• A letter of support from the residency training director, of no more than two pages (single spaced, no less than 12 pt. font and 1” margins).
• A letter of support from the proposed mentor, of no more than two pages (single spaced, no less than 12 pt. font and 1” margins), including a brief description on how he/she will play a key role in shaping and assisting the candidate in fulfilling the needs of this award.

RECOMMENDED ACTIVITIES

This award cannot be used to conduct basic or clinical research studies or trials. Awardees are to develop and execute a plan designed to increase their clinical knowledge of the management of SUD and complete a project aimed at improving the dissemination and/or adoption of existing evidence-based SUD treatment research findings. Secondary data analysis of treatment research datasets may be completed in pursuit of these aims, provided the project proposed is eligible for IRB exemption and has a dissemination/adoption focus but such projects still must address dissemination. Applications proposing non-exempt research involving human subjects that must be reviewed by an IRB under the requirements of the U.S. Department of Health and Human Services (HHS) regulations at 45 CFR part 46 will not be accepted.

Examples of appropriate activities and projects include but are not limited to:

• Reviewing available curricula or training programs; identifying status of education on SUD, especially opioid misuse, OUD diagnosis, and OUD management in various settings; and proposing and conducting activities to improve or increase the adoption of evidence-based practice;
• Identifying best practices or effective strategies or models for SUD education;
Developing materials that could be used for quality improvement or integration of an evidence-based approach or process in the management of SUD, including OUD, in a medical setting and conducting activities for quality improvement or adoption;

Identifying training gaps and research findings and/or products developed by NIDA or other federal agencies or professional associations that could bridge gaps, identifying potential partners for effective dissemination of these findings and disseminating them within existing or newly developed communication channels;

Coursework to strengthen formal training in substance use disorder research and;

Other activities consistent with the goals of the Dissemination Initiative to accelerate the dissemination of research findings and implementation or adoption of evidence-based SUD treatment in clinical practice.

Analysis of de-identified data from completed clinical trials such as those found on the NIDA Data Share website (https://datashare.nida.nih.gov/) to inform dissemination or implementation efforts; to characterize availability of data on substance use or practice patterns; identify gaps in the provision of evidence-based practices; and/or identify needs for dissemination or implementation.

RECOMMENDED CLINICAL TOPIC AREAS

Proposals must include components of evidence-based child and adolescent SUD treatment science. Recommended topic areas include:

- Screening and brief intervention for adolescents misusing opioids, marijuana, tobacco, alcohol, and other drugs including prescription medications;
- Smoking cessation for adolescent patients in the medical or behavioral healthcare system;
- Integrating substance abuse treatment for youth with(in) primary care or a medical home;
- Integration or augmentation of electronic health records to include substance misuse and substance use disorders in youth;
- Prescription drug misuse or use disorder in youth;
- Co-occurring disorders in youth; or
- Screening and management of HIV/Hepatitis/STD infections in adolescent patients with substance use disorders. AACAP will consider additional clinical topics that meet the criteria of direct relevance to child and adolescent substance use disorder treatment science and dissemination. For consideration of a topic not listed above, applicants must contact Carmen J. Thornton, MPH, AACAP Director of Research, Grants, and Workforce at research@aacap.org to discuss his/her topic before submitting an application.

AWARD REQUIREMENTS

- Applicants must be enrolled in a psychiatry, child psychiatry, or triple board program and be at the PGY2 level or higher.
- Applicants must be enrolled in a fully accredited general psychiatry or child and adolescent psychiatry clinical research or training program.
- Applicants must have a mentor who has had experience in substance use disorder treatment and/or research. It is preferred that the mentor’s work include children and adolescents. The mentor does not need to be a child psychiatrist by training.
- Candidates must not have any current or previous significant, individual project funding in the field of child and adolescent mental health. Candidates should not have had previous or simultaneous funding from the National Institutes of Health (NIH) or other research funding sources. Eligible candidates will not have a career development award.
- Applicants must either be AACAP members or have a membership application pending (not paid by the award) and agree to submit a proposal for a poster presentation on his or her activities or project for, and attend AACAP's 68th Annual Meeting in Atlanta, Georgia, October 25-30, 2021.
- Applicants must agree to attend the NIDA Clinical Trials Network's Annual Meeting tentatively scheduled for April 26-28, 2021 in Bethesda, MD. Cutting edge research will be presented at the NIDA CTN Annual Meeting and awardees will have the opportunity to network with other clinicians and researchers in the field.
- Recipients must submit a poster on preliminary work for the NIDA CTN Steering Committee meeting in April.
• Applications must be submitted via e-mail to Sarah Hellwege at research@aacap.org by 11:59 pm EST on Wednesday, November 4, 2020.

• All applicants must be available to attend by teleconference an orientation provided by The Bizzell Group, on behalf of NIDA, on December 18, 2020.

• All applicants are responsible for ensuring their own adherence to all federal research regulations, certifications and assurances. Institutional agreement of acceptance of their role and responsibility for the oversight of the award and proposed activities will be requested through the application process.

• Participants agree to participate in all annual surveys as part of the program evaluation process.

REPORTING REQUIREMENTS

• All award recipients will be required to submit a progress report detailing his/her work in April 2021.

• All award recipients will be required to submit a presentation on his/her project for the 68th AACAP Annual Meeting. All award recipients will be required to submit a final report detailing his/her work in December 2021.
### PERSONAL INFORMATION

<table>
<thead>
<tr>
<th>First Name:</th>
<th>Middle Initial:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name:</th>
<th>Degree(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Are you a Member of AACAP:**
- [ ] Yes.
- [ ] No. If no, do you have an application pending? [ ] Yes  [ ] No

Please list your resident year:

**Type of residency program:**

**Name of your institution:**

**Your title (if applicable):**

**Address:**

<table>
<thead>
<tr>
<th>City:</th>
<th>State:</th>
<th>Zip:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Work Phone:** [ ] ext.  **Email:**

**Home/Cell Phone:** [ ] ext.  **Fax:**

**Do you consider yourself to be:** [ ] Hispanic or Latino  **or**  [ ] Not Hispanic or Latino

**What race do you consider yourself to be?** Select one or more of the following:
- [ ] American Indian or Alaska Native
- [ ] Native Hawaiian or Other Pacific Islander
- [ ] Asian
- [ ] White
- [ ] Black or African American
- [ ] Prefer not to answer

### PRIMARY MENTOR INFORMATION

<table>
<thead>
<tr>
<th>First Name:</th>
<th>Last Name:</th>
<th>Degree:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Institution:**

**Address:**

<table>
<thead>
<tr>
<th>City:</th>
<th>State:</th>
<th>Zip:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Phone:** [ ] ext.  **Email:**

### PROJECT INFORMATION

**Project Title:**
Please indicate your agreement to attend the program orientation (by phone) on December 18, 2020, attend and present project update at the NIDA Clinical Trials Network’s Annual Meeting in Bethesda, MD, April 26-28, 2021, and attend and present at AACAP’s 68th Annual Meeting in Atlanta, Georgia, October 25-30, 2021 by initialing here:
(This is a program requirement).

Please indicate how you learned about this program:

**REVIEW PROCESS**

Applications will be reviewed by senior investigators with experience in related work in child and adolescent psychiatry research. Prior to the scientific review process, applications will undergo an administrative review process.

- **Administrative Review** – Applications will be reviewed for submission of all application materials. Incomplete applications or those that do not adhere to the application guidelines will not be forwarded for further review. Please ensure you meet the eligibility requirements and have submitted all requested application materials before finalizing your application.

- **Selection & Review** – Applications will undergo a scientific review process by senior child and adolescent psychiatrists with relevant expertise. Applications will be scored by the NIDA-AACAP Resident Training Award Program Selection Committee. The Selection Committee will prepare written reviews and score all applications. The review criteria are as follows:
  - Strength of the proposed activities or project plan, including conceptual or clinical framework, or information gathering plan;
  - Alignment with the goals of NIDA’s Dissemination Initiative;
  - Feasibility of the proposed activities or project to advance scientific knowledge or clinical practice in the field of child and adolescent psychiatry;
  - The applicant’s commitment and potential to become a champion of SUD evidence-based treatment in general medical settings and/or career investigator in the SUD field;
  - Endorsement, support, and qualifications of the applicant; and
  - Strength of commitment and support from the applicant’s host institution.

**SUPPORT FACILITIES**

The Applicant must submit letters of support if the proposed project uses facilities not routinely available to or directly under the supervision of the sponsoring program.

**INSTITUTIONAL SUPPORT**

The applicant assumes responsibility for conducting the project and the mentor for supervising the work and advanced education of the applicant and associates. The application must show that adequate and appropriately equipped space will be available during the funding period. If a project proposes secondary data analysis or when appropriate, projects must be eligible for and obtain IRB exemption.

**TERMS OF THE AWARD**

*Duration:* Applications will be accepted for one year of training only.

*Extension of Award Period:* In unusual circumstances, arrangements can be made for an extension of an award. Such a request must be made by the Awardee at least 60 days before the expiration date of the award. This request must be
made in writing, specify reasons for requesting the extension, and state a new expiration date. Project extensions of
greater than six months will not be considered.

Change of Status of Designated Mentor or Awardee: If the awardee changes affiliations or ceases work in the field for
which the award was made, the award will terminate and the remaining balance will be returned unless the awardee and
his or her new institution demonstrate the ability to successfully complete the planned project and the plan for this is
approved. If the named mentor changes affiliations or ceases work in the field for which the award was made, the
award will terminate and the remaining balance will be returned unless another appropriate mentor or plan to ensure
appropriate mentoring is identified and approved.

Location of Work: Awards are for projects in the United States at an accredited medical school, medical center, or
institution affiliated with a university teaching program. The awardee, with the direction of the mentor, will make all
arrangements for conduct of the proposed projects.

Liability of AACAP and National Institute on Drug Abuse: AACAP and NIDA assume no financial liability if patient
care responsibilities of any kind are undertaken by the NIDA awardee or mentor. The mentor, the awardee, and their
respective institution(s) acknowledge that NIDA and AACAP are not legally liable for the conduct of the Awardee or
the Mentor and associate investigators.

Patent Policy: The mentor, the awardee, and their respective institution(s) acknowledge that if a patentable invention or
discovery is conceived, or conceived and reduced to practice by the award during the term of the award year, NIDA
and AACAP must be apprised of the invention and the institution’s plans for protecting such invention under existing
institutional patent policy. AACAP will defer to institutional policies where they are in compliance with those of the
Federal government. NIDA and AACAP reserves the right where the institution has no patent policy, or policies not in
compliance with those of the Federal government, to claim rights and interests in the invention or discovery consistent
with FAR Clause 52.227-11, Patent Rights- Ownership by the Contractor.

AACAP reserves the right to cancel the award if terms and conditions are not met. AACAP maintains the right
to waive informalities.

☐ By submitting this document to AACAP, I indicate that I have read and agreed to the NIDA-AACAP
Resident Training Award in Substance Use Disorder Requirements.

APPLICATIONS DUE BY 11:59 pm EST
WEDNESDAY, NOVEMBER 4, 2020

Materials should be sent to Sarah Hellwege at research@aacap.org

All awards are contingent upon the receipt of adequate funding support.
AACAP has the right to waive informalities.